NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

$17.92 +0.08 (+0.45 %)
(As of 04/19/2018 08:07 AM ET)
Previous Close$17.84
Today's Range$17.81 - $18.01
52-Week Range$10.85 - $33.82
Volume4.71 million shs
Average Volume14.88 million shs
Market Capitalization$18.14 billion
P/E Ratio4.56
Dividend Yield2.43%
Beta0.67

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TEVA
CUSIPN/A
Phone972-3926-7267

Debt

Debt-to-Equity Ratio1.91%
Current Ratio0.86%
Quick Ratio0.58%

Price-To-Earnings

Trailing P/E Ratio4.56
Forward P/E Ratio7.79
P/E Growth1.55

Sales & Book Value

Annual Sales$22.39 billion
Price / Sales0.81
Cash Flow$6.2877 per share
Price / Cash2.85
Book Value$14.86 per share
Price / Book1.21

Profitability

EPS (Most Recent Fiscal Year)$3.93
Net Income$-16,265,000,000.00
Net Margins-72.66%
Return on Equity16.43%
Return on Assets4.91%

Miscellaneous

Employees51,792
Outstanding Shares1,016,880,000

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries declared a quarterly dividend on Thursday, November 2nd. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.90%. The ex-dividend date is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its quarterly earnings results on Thursday, February, 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.77 by $0.14. The company had revenue of $5.46 billion for the quarter, compared to analysts' expectations of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The firm's revenue was down 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.38 EPS. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.

What price target have analysts set for TEVA?

27 analysts have issued 12 month target prices for Teva Pharmaceutical Industries' shares. Their predictions range from $11.00 to $41.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $19.8654 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
  • 1. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
  • 2. According to Zacks Investment Research, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. " (1/12/2018)
  • 3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
  • 4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest in March. As of March 29th, there was short interest totalling 59,397,239 shares, a drop of 9.1% from the March 15th total of 65,322,254 shares. Based on an average daily trading volume, of 10,761,075 shares, the short-interest ratio is currently 5.5 days. Currently, 5.9% of the company's shares are sold short.

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:
  • Sol J. Barer Ph.D., Chairman of the Board (Age 69)
  • Kaare Schultz, President, Chief Executive Officer (Age 56)
  • Michael McClellan, Chief Financial Officer, Executive Vice President
  • Iris Beck-Codner, Executive Vice President - Global Brand & Communications (Age 52)
  • Richard Daniell, Executive Vice President - European Commercial
  • Carlo de Notaristefani, Executive Vice President - Global Operations (Age 59)
  • Sven Dethlefs Ph.D., Executive Vice President - Global Marketing & Portfolio
  • Hafrun Fridriksdottir, Executive Vice President - Global R&D (Age 55)
  • Gianfranco Nazzi, Executive Vice President - Growth Markets Commercial
  • Brendan O'Grady, Executive Vice President - North America Commercial

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News headlines about TEVA stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.17 on Accern's scale. They also assigned news stories about the company an impact score of 45.80 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional investors include ALLERGAN PLC (3.90%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $17.92.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $18.14 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  970 (Vote Outperform)
Underperform Votes:  844 (Vote Underperform)
Total Votes:  1,814
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
27 Wall Street analysts have issued ratings and price targets for Teva Pharmaceutical Industries in the last 12 months. Their average twelve-month price target is $19.8654, suggesting that the stock has a possible upside of 10.86%. The high price target for TEVA is $41.00 and the low price target for TEVA is $11.00. There are currently 7 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.961.962.072.04
Ratings Breakdown: 7 Sell Rating(s)
14 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
7 Sell Rating(s)
14 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
16 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
16 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.8654$20.7963$21.2654$25.6625
Price Target Upside: 10.86% upside16.12% upside1.00% downside72.23% upside

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Price Target History for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018Credit Suisse GroupSet Price TargetBuy$23.00HighView Rating Details
3/26/2018Royal Bank of CanadaReiterated RatingHold$16.00LowView Rating Details
3/20/2018Jefferies GroupInitiated CoverageHold -> Hold$19.00MediumView Rating Details
3/1/2018Maxim GroupReiterated RatingHoldMediumView Rating Details
2/13/2018Wells FargoReiterated RatingSellMediumView Rating Details
2/9/2018Bank of AmericaLower Price TargetUnderperform -> Underperform$17.00 -> $16.00LowView Rating Details
2/9/2018Leerink SwannLower Price TargetUnderweight -> Underperform$17.00 -> $16.00HighView Rating Details
2/9/2018Deutsche BankLower Price TargetHold -> Hold$20.00 -> $18.00MediumView Rating Details
2/9/2018GabelliDowngradeBuy -> Hold$19.00MediumView Rating Details
2/9/2018Piper JaffrayDowngradeNeutral -> Underweight$11.00MediumView Rating Details
2/8/2018Cantor FitzgeraldSet Price TargetHold$18.00MediumView Rating Details
2/8/2018OppenheimerReiterated RatingHoldMediumView Rating Details
2/2/2018BTIG ResearchDowngradeNeutral -> Sell$17.00LowView Rating Details
1/25/2018Susquehanna BancsharesReiterated RatingPositive -> Positive$22.00 -> $24.00MediumView Rating Details
1/11/2018Goldman SachsBoost Price TargetBuy$20.00 -> $25.00HighView Rating Details
1/9/2018MizuhoUpgradeNeutral -> Buy$19.12 -> $23.00N/AView Rating Details
1/4/2018CitigroupUpgradeNeutral -> Buy$24.00LowView Rating Details
12/18/2017UBSSet Price TargetHold$12.00 -> $20.00LowView Rating Details
12/15/2017Morgan StanleyUpgradeUnderweight -> Equal Weight$18.00MediumView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$16.00HighView Rating Details
11/13/2017JPMorgan ChaseDowngradeNeutral -> Underweight$11.48 -> $11.00N/AView Rating Details
10/25/2017Evercore ISISet Price TargetBuy$38.00N/AView Rating Details
10/20/2017BarclaysSet Price TargetHold$21.00 -> $19.00N/AView Rating Details
10/4/2017CowenReiterated RatingMarket Perform$30.00 -> $18.00N/AView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Earnings by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.58$0.63$0.61
Q2 20182$0.52$0.59$0.56
Q3 20182$0.49$0.55$0.52
Q4 20182$0.50$0.51$0.51

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018        
2/8/2018Q4 17$0.77$0.91$5.2870 billion$5.4590 billionViewListenView Earnings Details
11/2/2017Q3 2017$1.03$0.95$5.6065 billion$5.61 billionViewN/AView Earnings Details
8/3/20176/30/2017$1.06$0.99$5.7168 billion$5.6860 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.6885 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.7132 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.0590 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
11/2/2010Q3 2010$1.27$1.30ViewN/AView Earnings Details
7/26/2010Q2 2010$1.04$1.08ViewN/AView Earnings Details
5/4/2010Q1 2010$0.89$0.92ViewN/AView Earnings Details
2/16/2010Q4 2009$0.95$0.94ViewN/AView Earnings Details
11/3/2009Q3 2009$0.88$0.89ViewN/AView Earnings Details
7/28/2009Q2 2009$0.80$0.83ViewN/AView Earnings Details
5/5/2009Q1 2009$0.67$0.72ViewN/AView Earnings Details
2/17/2009Q4 2008$0.73$0.76ViewN/AView Earnings Details
11/6/2008Q3 2008$0.69$0.72ViewN/AView Earnings Details
7/29/2008Q2 2008$0.64$0.65ViewN/AView Earnings Details
5/6/2008Q1 2008$0.63$0.64ViewN/AView Earnings Details
2/12/2008Q4 2007$0.66$0.69ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Teva Pharmaceutical Industries pays an annual dividend of $0.43 per share, with a dividend yield of 2.40%. TEVA's most recent quarterly dividend payment was Tuesday, December 12. Teva Pharmaceutical Industries pays out 10.94% of its earnings out as a dividend.
Most Recent Dividend:12/12/2017
Annual Dividend:$0.43
Dividend Yield:2.40%
Dividend Growth:-14.40% (3 Year Average)
Payout Ratio:10.94% (Trailing 12 Months of Earnings)
18.70% (Based on This Year's Estimates)
17.20% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/2/2017quarterly$0.08502.74%11/27/201711/28/201712/12/2017
8/7/2017quarterly$0.08501.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.28902/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.32102.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.35302.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.34702.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.32603.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.32203.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.32208/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 58.22%
Insider Trading History for Teva Pharmaceutical Industries (NYSE:TEVA)
Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2018Deborah A GriffinInsiderSell943$17.88$16,860.84View SEC Filing  
3/19/2018Michael James McclellanCFOSell287$17.88$5,131.56View SEC Filing  
3/19/2018Richard DaniellVPSell1,297$17.89$23,203.331,297View SEC Filing  
3/19/2018Sven DethlefsEVPSell571$17.88$10,209.485,016View SEC Filing  
3/5/2018Brendan P O'gradyEVPSell705$19.38$13,662.90View SEC Filing  
3/5/2018Deborah A GriffinInsiderSell773$19.38$14,980.74View SEC Filing  
3/5/2018Richard DaniellVPSell1,108$19.28$21,362.24View SEC Filing  
2/15/2018Mark SabagEVPSell5,050$19.68$99,384.0044,517View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

Source:
DateHeadline
Active Pharmaceutical Ingredient (API) Market is is Forecast to Cross US$ 219.00 Billion By 2023Active Pharmaceutical Ingredient (API) Market is is Forecast to Cross US$ 219.00 Billion By 2023
www.marketwatch.com - April 19 at 8:02 AM
BRIEF-Teva And P&G Have Agreed To Terminate The PGT Healthcare PartnershipBRIEF-Teva And P&G Have Agreed To Terminate The PGT Healthcare Partnership
www.reuters.com - April 19 at 8:02 AM
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare PartnershipTeva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership
finance.yahoo.com - April 19 at 8:02 AM
P&G sales, earnings per share climbP&G sales, earnings per share climb
finance.yahoo.com - April 19 at 8:02 AM
Heritage Pharma Announces Executive Leadership ChangesHeritage Pharma Announces Executive Leadership Changes
www.prnewswire.com - April 18 at 5:57 PM
Novartis’s 1Q18 Estimates: Expectations for SandozNovartis’s 1Q18 Estimates: Expectations for Sandoz
finance.yahoo.com - April 18 at 8:03 AM
Teva Pharmaceutical Industries Ltd Forecasted to Earn Q1 2018 Earnings of $0.63 Per Share (TEVA)Teva Pharmaceutical Industries Ltd Forecasted to Earn Q1 2018 Earnings of $0.63 Per Share (TEVA)
www.americanbankingnews.com - April 18 at 7:40 AM
AbbVie’s Imbruvica in 4Q17 and Fiscal 2017AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
finance.yahoo.com - April 17 at 8:07 AM
Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of NeurologyTeva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology
finance.yahoo.com - April 17 at 8:07 AM
FY2021 EPS Estimates for Teva Pharmaceutical Industries Ltd Lowered by Leerink Swann (TEVA)FY2021 EPS Estimates for Teva Pharmaceutical Industries Ltd Lowered by Leerink Swann (TEVA)
www.americanbankingnews.com - April 17 at 7:05 AM
Jefferies Group Reiterates Hold Rating for Teva Pharmaceutical Industries (TEVA)Jefferies Group Reiterates Hold Rating for Teva Pharmaceutical Industries (TEVA)
www.americanbankingnews.com - April 16 at 12:37 PM
UPDATE 1-Israeli unions warn Teva Pharm over plan to close Ashdod plantUPDATE 1-Israeli unions warn Teva Pharm over plan to close Ashdod plant
www.reuters.com - April 16 at 8:03 AM
Who Blinks First, Teva Or Histadrut?Who Blinks First, Teva Or Histadrut?
seekingalpha.com - April 16 at 8:03 AM
Teva Pharmaceutical Industries Ltd (TEVA) Short Interest UpdateTeva Pharmaceutical Industries Ltd (TEVA) Short Interest Update
www.americanbankingnews.com - April 16 at 3:03 AM
Israeli unions warn Teva Pharm over plan to close Ashdod plantIsraeli unions warn Teva Pharm over plan to close Ashdod plant
finance.yahoo.com - April 15 at 8:51 AM
Oppenheimer Downgrades Teva Pharmaceutical Industries (TEVA) to Market PerformOppenheimer Downgrades Teva Pharmaceutical Industries (TEVA) to Market Perform
www.americanbankingnews.com - April 13 at 6:01 PM
Teva Pharmaceutical Industries (TEVA) PT Set at $39.00 by Credit Suisse GroupTeva Pharmaceutical Industries (TEVA) PT Set at $39.00 by Credit Suisse Group
www.americanbankingnews.com - April 13 at 6:01 PM
UBS Downgrades Teva Pharmaceutical Industries (TEVA) to Market PerformUBS Downgrades Teva Pharmaceutical Industries (TEVA) to Market Perform
www.americanbankingnews.com - April 13 at 6:01 PM
US appeals court strikes down Maryland drug price-gouging lawUS appeals court strikes down Maryland drug price-gouging law
www.reuters.com - April 13 at 5:47 PM
Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Credit Suisse GroupTeva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - April 12 at 2:52 PM
Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Cantor FitzgeraldTeva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - April 12 at 2:19 PM
Jefferies Group Reaffirms Hold Rating for Teva Pharmaceutical Industries (TEVA)Jefferies Group Reaffirms Hold Rating for Teva Pharmaceutical Industries (TEVA)
www.americanbankingnews.com - April 11 at 7:53 PM
Deutsche Bank Reaffirms Buy Rating for Teva Pharmaceutical Industries (TEVA)Deutsche Bank Reaffirms Buy Rating for Teva Pharmaceutical Industries (TEVA)
www.americanbankingnews.com - April 11 at 7:53 PM
Teva Pharmaceutical Industries (TEVA) Downgraded by Zacks Investment ResearchTeva Pharmaceutical Industries (TEVA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:44 PM
The Major Pharma Stocks That Are Making Short Sellers SickThe Major Pharma Stocks That Are Making Short Sellers Sick
www.msn.com - April 11 at 5:51 PM
Are Drug Prices Too Low?Are Drug Prices Too Low?
finance.yahoo.com - April 11 at 8:07 AM
Mylan to buy MS drug marketing rights from Israels Mapi PharmaMylan to buy MS drug marketing rights from Israel's Mapi Pharma
www.reuters.com - April 10 at 5:43 PM
Teva Pharmaceutical’s Specialty Medicines Segment PerformanceTeva Pharmaceutical’s Specialty Medicines Segment Performance
finance.yahoo.com - April 10 at 8:09 AM
Teva Pharmaceutical Industries (TEVA) Neutral Rating Reiterated at MizuhoTeva Pharmaceutical Industries' (TEVA) Neutral Rating Reiterated at Mizuho
www.americanbankingnews.com - April 9 at 10:55 PM
Teva Pharmaceutical Industries (TEVA) Downgraded to D+ at TheStreetTeva Pharmaceutical Industries (TEVA) Downgraded to D+ at TheStreet
www.americanbankingnews.com - April 9 at 7:30 PM
Teva Pharm to close plant in Israel after no buyer foundTeva Pharm to close plant in Israel after no buyer found
finance.yahoo.com - April 9 at 5:35 PM
AssistRx co-founder: Why company took on Teva employees, lease in OPAssistRx co-founder: Why company took on Teva employees, lease in OP
finance.yahoo.com - April 9 at 5:35 PM
Teva Pharmaceutical Industries (TEVA) Upgraded to "Buy" by ValuEngineTeva Pharmaceutical Industries (TEVA) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 8 at 10:47 AM
 Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Announce Quarterly Sales of $4.77 Billion Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Announce Quarterly Sales of $4.77 Billion
www.americanbankingnews.com - April 6 at 4:32 AM
Teva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target by Credit Suisse Group AnalystsTeva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 5 at 11:20 AM
Teva Pharmaceutical Industries (TEVA) PT Set at $38.00 by Evercore ISITeva Pharmaceutical Industries (TEVA) PT Set at $38.00 by Evercore ISI
www.americanbankingnews.com - April 4 at 9:36 PM
Teva, Valeant Exposed By Californias Drug Transparency LawTeva, Valeant Exposed By California's Drug Transparency Law
seekingalpha.com - April 4 at 4:27 PM
$0.67 Earnings Per Share Expected for Teva Pharmaceutical Industries Ltd (TEVA) This Quarter$0.67 Earnings Per Share Expected for Teva Pharmaceutical Industries Ltd (TEVA) This Quarter
www.americanbankingnews.com - April 4 at 5:13 AM
Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by MizuhoTeva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - April 4 at 12:34 AM
Teva sells OP business segmentTeva sells OP business segment
finance.yahoo.com - April 3 at 5:46 PM
Today’s Research Reports on Stocks to Watch: Alkermes and TevaToday’s Research Reports on Stocks to Watch: Alkermes and Teva
finance.yahoo.com - April 3 at 5:46 PM
Teva Pharmaceutical Industries (TEVA) Upgraded to "Strong-Buy" at ValuEngineTeva Pharmaceutical Industries (TEVA) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - April 2 at 11:26 PM
How Novartis’s Cardio-Metabolic and Neuroscience Segments PerformedHow Novartis’s Cardio-Metabolic and Neuroscience Segments Performed
finance.yahoo.com - April 2 at 8:06 AM
Teva Pharmaceutical Industries (TEVA) Given a $18.00 Price Target by Cantor Fitzgerald AnalystsTeva Pharmaceutical Industries (TEVA) Given a $18.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 31 at 12:42 PM
Teva Pharmaceutical Industries (TEVA) Rating Increased to Hold at Zacks Investment ResearchTeva Pharmaceutical Industries (TEVA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 10:56 AM
CORRECTED-UPDATE 2-Teva wins reversal of U.S. jurys $235 mln GSK drug patent verdictCORRECTED-UPDATE 2-Teva wins reversal of U.S. jury's $235 mln GSK drug patent verdict
www.cnbc.com - March 30 at 5:45 PM
Stark Wipes Out $235M Infringement Verdict Against Teva for Hypertension DrugStark Wipes Out $235M Infringement Verdict Against Teva for Hypertension Drug
finance.yahoo.com - March 30 at 5:45 PM
Teva Pharmaceutical Industries (TEVA) Lifted to "Buy" at CitigroupTeva Pharmaceutical Industries (TEVA) Lifted to "Buy" at Citigroup
www.americanbankingnews.com - March 30 at 5:08 PM
Mizuho Upgrades Teva Pharmaceutical Industries (TEVA) to BuyMizuho Upgrades Teva Pharmaceutical Industries (TEVA) to Buy
www.americanbankingnews.com - March 30 at 12:12 PM
Teva wins reversal of US jurys $235 mln GSK drug patent verdictTeva wins reversal of US jury's $235 mln GSK drug patent verdict
www.reuters.com - March 30 at 8:04 AM

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.